How (and when) is primary refractory AL amyloidosis defined following D-CyBorD treatment? Is there a threshold of biomarker reduction following 1-2 cycles that, if not met, should prompt early consideration of treatment change?
How (and when) is primary refractory AL amyloidosis defined following D-CyBorD treatment? Is there a threshold of biomarker reduction following 1-2 cycles that, if not met, should prompt early consideration of treatment change? | Mednet
